Related Experiment Videos
Ciprofloxacin in urinary tract infections
1Statens Seruminstitut's Department of Clinical Microbiology Rigshospitalet, Copenhagen, Denmark.
Scandinavian Journal of Infectious Diseases. Supplementum
|January 1, 1989
Summary
Ciprofloxacin demonstrates strong in vitro effectiveness against urinary tract infection pathogens. Clinical trials confirm its safety and efficacy, comparable to existing treatments.
Area of Science:
- Pharmacology and Microbiology
- Clinical Therapeutics
Background:
- Urinary tract infections (UTIs) are common, necessitating effective antimicrobial agents.
- Ciprofloxacin, a fluoroquinolone antibiotic, exhibits broad-spectrum activity.
Purpose of the Study:
- To evaluate the therapeutic potential of ciprofloxacin for urinary tract infections.
- To assess the clinical efficacy and safety profile of ciprofloxacin compared to other treatments.
Main Methods:
- In vitro susceptibility testing against common urinary tract pathogens.
- Review of controlled clinical trials comparing ciprofloxacin with established UTI therapies.
Main Results:
- Ciprofloxacin exhibited high in vitro activity against a majority of UTI pathogens.
- Published clinical trials indicated ciprofloxacin is well-tolerated with few adverse reactions.
- Efficacy of ciprofloxacin was found to be non-inferior to comparator drugs.
Conclusions:
- Ciprofloxacin possesses significant potential for treating urinary tract infections due to its potent antimicrobial activity and favorable pharmacokinetics.
- Clinical evidence supports the use of ciprofloxacin as a safe and effective option for UTI management.